Immunological analysis of a Lactococcus lactis-based DNA vaccine expressing HIV gp120
Open Access
- 29 January 2007
- journal article
- research article
- Published by Springer Nature in Genetic Vaccines and Therapy
- Vol. 5 (1) , 3
Abstract
For reasons of efficiencyEscherichia coliis used today as the microbial factory for production of plasmid DNA vaccines. To avoid hazardous antibiotic resistance genes and endotoxins from plasmid systems used nowadays, we have developed a system based on the food-gradeLactococcus lactisand a plasmid without antibiotic resistance genes. We compared theL. lactissystem to a traditional one inE. coliusing identical vaccine constructs encoding the gp120 of HIV-1. Transfection studies showed comparable gp120 expression levels using both vector systems. Intramuscular immunization of mice withL. lactisvectors developed comparable gp120 antibody titers as mice receivingE. colivectors. In contrast, the induction of the cytolytic response was lower using theL. lactisvector. Inclusion of CpG motifs in the plasmids increased T-cell activation more when theE. colirather than theL. lactisvector was used. This could be due to the different DNA content of the vector backbones. Interestingly, stimulation of splenocytes showed higher adjuvant effect of theL. lactisplasmid. The study suggests the developedL. lactisplasmid system as new alternative DNA vaccine system with improved safety features. The different immune inducing properties using similar gene expression units, but different vector backbones and production hosts give information of the adjuvant role of the silent plasmid backbone. The results also show that correlation between thein vitroadjuvanticity of plasmid DNA and its capacity to induce cellular and humoral immune responses in mice is not straight forward.Keywords
This publication has 37 references indexed in Scilit:
- Enhanced cell-mediated IFN-γ-secreting activity against the HIV-1IIIB V3 peptide of the TAB9 multiepitope after DNA vaccine backbone engineeringBiochemical and Biophysical Research Communications, 2003
- Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotidesEuropean Journal of Immunology, 2003
- Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boostJournal of General Virology, 2003
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial AntigensJournal of Experimental Medicine, 2001
- Construction, Biological Activity, and Immunogenicity of Synthetic Envelope DNA Vaccines Based on a Primary, CCR5-Tropic, Early HIV Type 1 Isolate (BX08) with Human CodonsAIDS Research and Human Retroviruses, 2000
- Spontaneous Silencing of Humanized Green Fluorescent Protein (hGFP) Gene Expression from a Retroviral Vector by DNA MethylationJournal of Hematotherapy, 1998
- Hexamer Palindromic Oligonucleotides with 5′CG-3′ Motif(s) Induce Production of InterferonJournal of Interferon & Cytokine Research, 1996
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- Sensitive ELISA for the gp120 and gp160 Surface Glycoproteins of HIV-1AIDS Research and Human Retroviruses, 1988